| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/02/2004 | WO2003015697A3 Interleukin-2 mutants with reduced toxicity |
| 09/02/2004 | WO2003000200A3 β-2'-OR 3'-HALONUCLEOSIDES |
| 09/02/2004 | WO2002074289A3 Antitumor compositions containing taxane derivatives |
| 09/02/2004 | US20040172112 Methods for treating prostatitis |
| 09/02/2004 | US20040171908 Cardiac disease treatment and device |
| 09/02/2004 | US20040171907 Cardiac disease treatment and device |
| 09/02/2004 | US20040171832 Novel sulfonate substituted pyrazol pyridine derivatives |
| 09/02/2004 | US20040171804 for drug screening cancer, osteoporosis, obesity, Alzheimer's disease drugs; genetic engineering; kits |
| 09/02/2004 | US20040171695 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 09/02/2004 | US20040171693 Increasing dermal papilla cell proliferation using topical creatine formulation |
| 09/02/2004 | US20040171678 Reduced toxicity; blocking p-glycoprotein membrane toxin extrusion pump |
| 09/02/2004 | US20040171669 Rapid disintegration on contact with saliva forming easy to swallow palatable suspension; tablets |
| 09/02/2004 | US20040171664 Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event |
| 09/02/2004 | US20040171660 Single dose aromatase inhibitor for treating infertility |
| 09/02/2004 | US20040171646 Novel substituted benzimidazole dosage forms and method of using same |
| 09/02/2004 | US20040171637 anticancer agents; in admixture with one or more pharmaceutically acceptable carriers or diluents and a known chemotherapeutic agent |
| 09/02/2004 | US20040171636 Treatment of viral infections |
| 09/02/2004 | US20040171630 both receptor-type and non-receptor type tyrosine kinases; to treat angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, |
| 09/02/2004 | US20040171622 Cardioprotective delta opioid receptor agonists and methods of using same |
| 09/02/2004 | US20040171597 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| 09/02/2004 | US20040171593 Method and compositions for treating an inflammatory disease |
| 09/02/2004 | US20040171589 Differential delivery of nitric oxide |
| 09/02/2004 | US20040171584 formulations of ANGIOTENSIN II AT1 receptors antagonists, using the cyclodextrins or their derivatives, lipossomes and the biodegradable polymers; increasing the bio-availability of losartan |
| 09/02/2004 | US20040171576 with the proviso that the anticholinergic agent is not a tiotropium salt; asthma, chronic obstructive pulmonary disease |
| 09/02/2004 | US20040171568 oligonucleotide at least 29 nucleotides in length, wherein the anti-HIV activity of said oligonucleotide occurs principally by a non-sequence complementary mode of action |
| 09/02/2004 | US20040171557 treating or educating said cells ex vivo in the presence of: intermediary metabolite; antigens or epitopes associated with said disease, or the immune-mediated inflammatory response; re-administering to said subject said treated or educated cells |
| 09/02/2004 | US20040171555 inhibitors of dipeptidyl peptidase; treatment of impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy and nephropathy and of sequelae of diabetes mellitus in mammals |
| 09/02/2004 | US20040171546 Regulation of lung tissue by hedgehog-like polypeptides and formulations and uses related thereto |
| 09/02/2004 | US20040171544 treating or preventing epithelial lesions in a mammal (e.g., a human) using trefoil domain-containing polypeptides |
| 09/02/2004 | US20040171541 combination comprising a polypeptide comprising the modulating sequence of the erythropoietin receptor and a non-peptide organic molecule in the treatment of anemia |
| 09/02/2004 | US20040171532 coadministering a taxane and an oral bioavailability enhancing agent inhibitor of p-glycoprotein; preventing or reducing hypersensitivity or allergic reactions; anticancer agents |
| 09/02/2004 | US20040171528 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171527 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/02/2004 | US20040171526 Raise intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171522 Raise the intracellular or extracellular or serum level of metabolite in subject |
| 09/02/2004 | US20040171520 Melanocortin receptor-specific peptidomimetics |
| 09/02/2004 | US20040171122 Gm-csf and/or defensin protein expression regulators in epithelial cells comprising ets transcription factor or gene encoding the same |
| 09/02/2004 | US20040171107 Modified flourescent proteins |
| 09/02/2004 | US20040171080 Method of assaying for agonists or antagonist of dynorphin a binding to the mas receptor |
| 09/02/2004 | US20040171074 Structures of substrate binding pockets of SCF complexes |
| 09/02/2004 | US20040171018 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 09/02/2004 | US20040171012 Nucleic acid-associated proteins |
| 09/02/2004 | US20040170999 Nuclear hormone receptor ligand binding domain |
| 09/02/2004 | US20040170993 Methods for diagnosing and treating heart disease |
| 09/02/2004 | US20040170980 Molecules capable of binding to telomere and the like and method with the use of the same |
| 09/02/2004 | US20040170973 DNA encoding the human serine protease EOS |
| 09/02/2004 | US20040170969 GRF2 binding proteins and applications thereof |
| 09/02/2004 | US20040170959 Methods for identifying antiviral oligonucleotides |
| 09/02/2004 | US20040170713 To promote good health and as a dietary additive |
| 09/02/2004 | US20040170698 Water-soluble mixture of polyethylene glycol and sodium phosphate; useful for preparing the bowel prior to surgery or diagnostic procedures such as colonoscopies |
| 09/02/2004 | US20040170681 Fast acting paracetamol formulation containing a small amount of antacid |
| 09/02/2004 | US20040170678 Liposomal antineoplastic drugs and uses thereof |
| 09/02/2004 | US20040170663 Priming extracellular matrix by treating with a priming agent; adding to the primed extracellular matrix a solution of a polymerizable agent; reacting the primed extracellular matrix and polymerizable agent to create a hydrogel covalently bound to the extracellular matrix |
| 09/02/2004 | US20040170654 bolus injection to skin; increased systemic absorption produced compared to absorption produced on delivering the agonist subcutaneously by bolus injection; particularly applicable to tricyclic nitrogen-containing compounds, e.g., R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5-ij]-quinoline-2(1H)-thione |
| 09/02/2004 | US20040170649 uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact; autologous vaccines |
| 09/02/2004 | US20040170635 administering an inhibitor of the CD2/LFA-3 interaction, in combination with narrow band UVB radiation; especially for treating psoriasis |
| 09/02/2004 | US20040170627 Antagonists of Myelin-associated Glycoprotein and their use in the treatment and/or prevention of Neurological diseases |
| 09/02/2004 | US20040170624 active principle, especially the humanized monoclonal antibody JAQ1, that induces irreversible inactivation or degradation of the collagen receptor on thrombocytes; diagnostic agent for the determination of the expression rate of the collagen receptor GPVI |
| 09/02/2004 | US20040170620 Selected antibody compositions for binding to aminophospholipids |
| 09/02/2004 | US20040170618 antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. |
| 09/02/2004 | US20040170613 Compositions and methods for liver growth and liver protection |
| 09/02/2004 | US20040170611 culturing an autologous or allogenic dermal papilla cell in the presence of a Wnt polypeptide or a fragment or analog thereof, and grafting the cultured cell onto the skin |
| 09/02/2004 | US20040170603 Using radiolabeled annexin; radiotherapy for tumors |
| 09/02/2004 | US20040170573 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 09/02/2004 | US20040170569 Dosage forms that rapidly produces peak plasma concentrations; heating a thin layer of the drug on a solid support to form a vapor; and passing air through the heated vapor to produce aerosol particles having less than 10% drug degradation products |
| 09/02/2004 | US20040170568 Stabilized preparations for use in metered dose inhalers |
| 09/02/2004 | DE19910682B4 Verwendung eines Kombinationspräparates zur Therapie einer Fibrat-induzierten Hyperhomocysteinämie The use of a combination product for the treatment of a fibrate-induced hyperhomocysteinemia |
| 09/02/2004 | CA2833559A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2517005A1 A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| 09/02/2004 | CA2516475A1 Oxazole-derivatives as ppar agonists |
| 09/02/2004 | CA2516097A1 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
| 09/02/2004 | CA2515929A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2515567A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | CA2514804A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 09/02/2004 | CA2514061A1 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | CA2512883A1 Sulfonamide derivatives as ppar modulators |
| 09/01/2004 | EP1452600A1 Receptor and nucleic acid molecule encoding said receptor |
| 09/01/2004 | EP1452530A1 Azole compound and medicinal use thereof |
| 09/01/2004 | EP1452526A1 Indole compound and medicinal use thereof |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1451856A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451578A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 09/01/2004 | EP1451577A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
| 09/01/2004 | EP1451369A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
| 09/01/2004 | EP1451364A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 09/01/2004 | EP1451337A2 Nogo receptor-mediated blockade of axonal growth |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451294A2 Nutrient medium for maintaining neural cells in injured nervous system |
| 09/01/2004 | EP1451227A2 Method for controlling angiogenesis in animals |
| 09/01/2004 | EP1451219A1 Nuclear protein "shoca" - a component of the wnt signalling pathway |
| 09/01/2004 | EP1451212A2 Structural and cytoskeleton-associated proteins |
| 09/01/2004 | EP1451205A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451184A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451183A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451182A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451181A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451167A1 Phenylalkynes |